english.prescrire.org > Spotlight > 100 most recent > In the February issue of Prescrire International: Rituximab (Mabthera° or other brands) in certain non-Hodgkin lymphomas in children

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

In the February issue of Prescrire International: Rituximab (Mabthera° or other brands) in certain non-Hodgkin lymphomas in children

FREE DOWNLOAD In the "Marketing Authorisations" section of the February issue: what do Prescrire's editors make of the data regarding this new indication for rituximab?
Full text available for free download.

Prescrire's rating

  •  POSSIBLY HELPFUL  Rituximab has been authorised in the European Union as first-line treatment for children with certain non-Hodgkin lymphomas... The harm-benefit balance of rituximab in children seems to be similar to that in adults.

©Prescrire 1 February 2022

Source: "Rituximab (Mabthera° or other brands) in certain non-Hodgkin lymphomas in children" Prescrire International 2022; 31 (234): 43. Free.

Enjoy full access to Prescrire International, and support independent information
Share
Share on Facebook Share on Twitter


See also:

"Rituximab (Mabthera° or
other brands) in pemphigus
vulgaris: more patients
in remission than with other
immunosuppressants, lower
exposure to corticosteroids,
but a risk of cancer"
(May 2021)
Free

Numerous other texts
available via the "Search"
function, using the keyword
"rituximab"
Search


Read more:

All the subjects in
Prescrire's Spotlight
Free >